Medical device reimbursement will never be the same.
“This is a brave new world when it comes to reimbursement,” said Tom Hughes, senior principal adviser for health economics and reimbursement at Minneapolis-based RCRI.
It’s still a volume, fee-based model in the United States. But there is also tremendous change — and great opportunities out there for medical device companies of all sizes meeting an unmet need — saving costs and improving quality of care, according to Hughes.